Altace Patent Trial Set To Begin Feb. 13
This article was originally published in The Pink Sheet Daily
Executive Summary
King Therapeutics' defense against generic competition of ACE inhibitor Altace (ramipril) is scheduled to go to trial in Boston federal court Feb. 13, CEO Brian Markison said Feb. 7 during the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference